US EditionPublished • loading... • Updated
Stj Sees Patent Extension for Ozempic
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
By decision, starting in March 2026, generics may be produced in Brazil
·Brazil
Read Full Article
The Supreme Court of Justice (STJ) has today rejected a request from New Nordisk for 12 years to extend the patent of semi-maturity, the active principle of Ozempic and Rybelsus. Thus, the patent will even expire in March 2026, opening the way for the production of generics in the country. The New Nordisk can still appeal to the Supreme. “The legal clarity on the subject is positive for pharmaceuticals and pharmaceuticals that are preparing to l…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
